Jane Street Group, LLC Editas Medicine, Inc. Call Options Transaction History

Jane Street Group, LLC

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $37,629 - $66,156	11,100 New	11,100 $37,000
Q1 2022 May 17, 2022	BUY	$14.08 - $27.63 $737,792 - $1.45 Million	52,400 Added 49.16%	159,000 $3.02 Million
Q4 2021 Feb 15, 2022	SELL	$26.55 - $40.57 $8.29 Million - $12.7 Million	-312,400 Reduced 74.56%	106,600 $2.83 Million
Q3 2021 Nov 16, 2021	SELL	$39.27 - $72.94 $13.6 Million - $25.3 Million	-347,500 Reduced 45.34%	419,000 $17.2 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $15 Million - $27.2 Million	480,000 Added 167.54%	766,500 $43.4 Million
Q1 2021 May 18, 2021	SELL	$39.71 - $90.58 $6.98 Million - $15.9 Million	-175,800 Reduced 38.03%	286,500 $12 Million
Q4 2020 Feb 17, 2021	BUY	$27.07 - $84.35 $5.38 Million - $16.8 Million	198,700 Added 75.38%	462,300 $32.4 Million
Q3 2020 Nov 17, 2020	SELL	$28.06 - $37.16 $3.44 Million - $4.56 Million	-122,700 Reduced 31.76%	263,600 $7.4 Million
Q2 2020 Aug 17, 2020	BUY	$18.5 - $34.34 $6.71 Million - $12.5 Million	362,900 Added 1550.85%	386,300 $11.4 Million
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $952,320 - $2.1 Million	-64,000 Reduced 73.23%	23,400 $464,000
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $298,197 - $499,239	15,300 Added 21.22%	87,400 $2.59 Million
Q3 2018 Nov 14, 2018	BUY	$27.65 - $38.39 $1.81 Million - $2.51 Million	65,500 Added 992.42%	72,100 $2.29 Million
Q2 2018 Aug 15, 2018	SELL	$31.4 - $41.01 $241,780 - $315,777	-7,700 Reduced 53.85%	6,600 $236,000
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $426,712 - $630,344	14,300 New	14,300 $474,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.